drugset / Trial / NCT00250250

An Open-Label, Multi-centre, Phase III Study of Local Tolerability of ZOMACTON 10MG

NCT00250250

Phase 3 Completed 27 enrolled Ferring Pharmaceuticals
RandomizedSingle-groupOpen-labelTreatment

Summary

Children with growth failure due to inadequate secretion of growth hormone or growth retardation due to Turner's syndrome are individually dosed and treated for 12 weeks

Timeline

Start
2005-10
Primary completion
2006-03
Completion
2006-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Somatropin Protein / enzyme biologic Subcutaneous

Indications